Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MINE
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MINE is a chemotherapy regimen composed of Ifosfamide, Mitoxantrone, and Etoposide, with Mesna included as a uroprotectant. This combination is utilized in the treatment of certain lymphomas, such as intermediate-grade or immunoblastic non-Hodgkin's lymphoma. The regimen works by combining drugs that interfere with cancer cell division and growth through distinct mechanisms, aiming to maximize therapeutic effect while managing side effects.
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on MINE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MINE.